TransThera Sciences (Nanjing), Inc. (2617) Completes H Share Placing and Raises Approximately HK$190.14 Million

Bulletin Express01-20 17:03

TransThera Sciences (Nanjing), Inc. (Stock Code: 2617) announced the completion of a placing of 2,100,000 new H shares under its general mandate. Placing shares were priced at HK$92.85 each, generating gross proceeds of about HK$194.99 million and net proceeds of around HK$190.14 million. According to the announcement, these new shares account for approximately 0.70% of the existing issued H share capital prior to completion and around 0.53% of total issued shares at that time.

The company stated that it plans to allocate about 60% of the proceeds to clinical trial and development expenses for its Core Product, Tinengotinib, 30% to the research and development of other products, and 10% to working capital and general corporate purposes. Following the placement, total issued shares of TransThera Sciences (Nanjing), Inc. increased from 396,897,633 to 398,997,633.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment